Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).


OBJECTIVES When advanced non-small-cell lung cancer (NSCLC) progresses during first-line treatment, re-biopsy may be indicated to detect a possible new biological profile (comparison to initial status, emergence of resistance biomarkers, or assessment of new biomarkers). The aim of this pragmatic prospective multicenter study was to assess the feasibility… (More)
DOI: 10.1016/j.lungcan.2014.08.016


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics